ArticleFrontiers in public health2022

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.

Zhuo-Miao Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.